Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APLS Apellis Pharmaceuticals Inc.

交易中 07-23 09:37:47 EDT

36.77

-0.28

-0.76%

最高37.09	最低36.74	成交量1.60万
今开36.74	昨收37.05	日振幅0.93%
总市值44.63亿	流通市值30.04亿	总股本1.21亿
成交额58.76万	换手率0.02%	流通股本8,170万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":36.77,"timestamp":1721741840408,"preClose":37.05,"halted":0,"volume":15975,"delay":0,"floatShares":81699796,"shares":121365555,"eps":-3.449984,"marketStatus":"交易中","marketStatusCode":2,"change":-0.28,"latestTime":"07-23 09:37:47 EDT","open":36.74,"high":37.085,"low":36.74,"amount":587589.9738749999,"amplitude":0.009312,"askPrice":36.97,"askSize":13,"bidPrice":36.77,"bidSize":141,"shortable":3,"etf":0,"ttmEps":-3.449984,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721764800000},"adr":0,"listingDate":1510203600000,"adjPreClose":37.05,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":38,"preClose":37.05,"latestTime":"09:04 EDT","volume":13,"amount":476.03998,"timestamp":1721739858690},"postHourTrading":{"tag":"盘后","latestPrice":37.05,"preClose":37.05,"latestTime":"18:52 EDT","volume":81447,"amount":3017611.35,"timestamp":1721688730908},"volumeRatio":0.605151,"impliedVol":0.9832,"impliedVolPercentile":0.7937},"requestUrl":"/m/hq/s/APLS/tweets","defaultTab":"tweets","newsList":[{"id":"2452743573","title":"Apellis Pharmaceuticals, Inc.盘中异动 快速跳水5.29%报37.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452743573","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452743573?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:30","pubTimestamp":1721316611,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日23时30分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.29%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.05%。其相关个股中，Silo Pharma, Inc.、Onconetix, Inc.、Salarius Pharmaceuticals, Inc.涨幅较大，Silo Pharma, Inc.、Salarius Pharmaceuticals, Inc.、Onconetix, Inc.较为活跃，换手率分别为2159.96%、1537.54%、1159.57%，振幅较大的相关个股有Silo Pharma, Inc.、Salarius Pharmaceuticals, Inc.、Onconetix, Inc.，振幅分别为93.33%、91.50%、86.24%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407182330119681e1c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407182330119681e1c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4588","BK4505","BK4585","APLS","BK4139","LU1093756168.USD"],"gpt_icon":0},{"id":"2452910329","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452910329","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452910329?lang=zh_cn&edition=full","pubTime":"2024-07-17 00:31","pubTimestamp":1721147510,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日00时31分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.15%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407170031519681d3d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407170031519681d3d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4139","LU1093756168.USD","BK4585","BK4505","APLS","BK4588"],"gpt_icon":0},{"id":"2450365091","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.44%报39.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450365091","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450365091?lang=zh_cn&edition=full","pubTime":"2024-07-11 21:50","pubTimestamp":1720705831,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日21时50分，Apellis Pharmaceuticals, Inc.股票出现波动，股价快速上涨5.44%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711215031aef93dca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711215031aef93dca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU1093756325.SGD","BK4588","LU1093756168.USD","APLS","BK4505","BK4139"],"gpt_icon":0},{"id":"2448060944","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.01%报36.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448060944","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448060944?lang=zh_cn&edition=full","pubTime":"2024-07-02 03:47","pubTimestamp":1719863233,"startTime":"0","endTime":"0","summary":"北京时间2024年07月02日03时47分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.01%。截至发稿，该股报36.44美元/股，成交量127.387万股，换手率1.05%，振幅6.62%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702034713968187c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702034713968187c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","APLS","BK4505","LU1093756325.SGD","BK4585","LU1093756168.USD"],"gpt_icon":0},{"id":"2448952768","title":"美国研究综述-AT&T, ATI, 加利福尼亚资源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2448952768","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448952768?lang=zh_cn&edition=full","pubTime":"2024-07-01 15:23","pubTimestamp":1719818605,"startTime":"0","endTime":"0","summary":"    路透7月1日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 AT&T、ATI 和加州资源公司。要闻  * AT&T Inc   ：摩根大通将其股票列入美国分析师关注名单  * ATI Inc   ：摩根大通将其股票从美国分析师关注名单中删除  * 加州资源公司   ：Gerdes Energy Research将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIVN","BK4144","CENT","WBA","BK4018","BK4187","BK4562","OVV","FCNCA","LU0053671581.USD","BK4207","BK4588","BK4196","INSM","BK4507","BK4139","LU1621768115.EUR","T","ATI","NKLA","LU0321505439.SGD","CRC","LU1621767810.EUR","SPB","RCKT","LU0109394709.USD","HXL","BK4505","IE00B19Z3581.USD","SM","IE00B7SZLL34.SGD","TSHA","ELAN","ILMN","KNTK","PTCT","LU2065732104.USD","BK4213","BK4211","APLS","BK4589","EQT","IE00BSNM7G36.USD","LU1621767737.EUR","NOG","BK4585","CHRS","ACCD","LU0889565916.HKD","BK4561"],"gpt_icon":0},{"id":"2446688212","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.13%报39.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446688212","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446688212?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:31","pubTimestamp":1719581518,"startTime":"0","endTime":"0","summary":"北京时间2024年06月28日21时31分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.13%。截至发稿，该股报39.39美元/股，成交量4.5046万股，换手率0.04%，振幅0.45%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628213159941f24e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240628213159941f24e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","LU1093756168.USD","BK4588","APLS","BK4139","LU1093756325.SGD","BK4585"],"gpt_icon":0},{"id":"2438321531","title":"HC Wainwright & Co.：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价由92.00美元调整至92.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2438321531","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438321531?lang=zh_cn&edition=full","pubTime":"2024-05-28 18:37","pubTimestamp":1716892634,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价由92.00美元调整至92.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528183717956e5b4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528183717956e5b4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"2437519250","title":"Apellis Pharmaceuticals, Inc.盘中异动 大幅上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437519250","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437519250?lang=zh_cn&edition=full","pubTime":"2024-05-24 23:11","pubTimestamp":1716563496,"startTime":"0","endTime":"0","summary":"北京时间2024年05月24日23时11分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.04%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：富国集团分析师Derek Archila维持$Apellis Pharmaceuticals $持有评级，并将目标价从57美元下调至48美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524231136af8a2f21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524231136af8a2f21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","BK4585","LU1093756168.USD","LU1093756325.SGD","APLS","BK4139"],"gpt_icon":0},{"id":"2437768483","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437768483","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437768483?lang=zh_cn&edition=full","pubTime":"2024-05-23 22:01","pubTimestamp":1716472881,"startTime":"0","endTime":"0","summary":"北京时间2024年05月23日22时01分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.18%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：富国集团分析师Derek Archila维持$Apellis Pharmaceuticals $持有评级，并将目标价从57美元下调至48美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240523220121941e9ac9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240523220121941e9ac9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS","BK4139","LU1093756168.USD","BK4585","BK4505","BK4588","LU1093756325.SGD"],"gpt_icon":0},{"id":"2436992749","title":"美国研究综述-Bath & Body Works、Under Armour、Viking Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2436992749","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436992749?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:51","pubTimestamp":1715943108,"startTime":"0","endTime":"0","summary":"    路透5月17日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Bath & Body Works、Under Armour 和 Viking Therapeutics。要闻  * Advanced Drainage Systems Inc   ：巴克莱将目标价从189美元上调至202美元             * Bath & Body Works Inc   ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。* Under Armour Inc   ：摩根大通将其评级从 \"中性 \"下调至 \"减持\"。* Viking Therapeutics Inc   ：Raymond James将其评级从 \"跑赢大盘 \"上调至 \"强力买入\"。* Abbvie Inc   ：Cantor Fitzgerald给予该公司 \"增持 \"评级，目标价200美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMTX","BK4589","COIN","AN","CSCO","DOCS","BKKT","ARRY","LU0348723411.USD","BBWI","OBDC","AZPN","APLS","ABBV","BK4227","CSWC","AMAT","LENZ","CCL","DE","WMS","FCNCA","CVI","DD","LU1291159041.SGD","BK4134","CPAY","FLO","COGT","FOR","BK4109","ACHR","CFG","IE00BLSP4452.SGD","BMRN","LU0823411888.USD","HEI","ANF","DHI","HLT","LU0208291251.USD","FOLD","LU0029864427.USD","CBRL","BURL","UA","CPRT","DXC","GPI","BAC"],"gpt_icon":0},{"id":"2436969363","title":"美国研究综述-迪尔公司、Under Armour、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2436969363","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436969363?lang=zh_cn&edition=full","pubTime":"2024-05-17 14:56","pubTimestamp":1715928964,"startTime":"0","endTime":"0","summary":"    路透5月17日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括迪尔公司、Under Armour 和沃尔玛。要闻              * Advanced Drainage Systems Inc   ：巴克莱将其目标价从189美元上调至202美元             * 迪尔公司  ：大和资本市场将目标价从400美元上调至440美元             * Under Armour Inc   ：摩根大通将其评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","TXT","LU2237443549.SGD","LU0323240290.USD","IE00BKVL7J92.USD","LU1267930490.SGD","TJX","IE0009355771.USD","LU0149725797.USD","LU2211817866.USD","LU0312595415.SGD","LU0757428866.USD","AMTX","LU2023250504.SGD","LU2237443382.USD","BK4112","CSWC","LU1093756325.SGD","LU0385154629.USD","BK4202","FOLD","LU1720051017.SGD","COGT","LU1169590202.USD","DE","UAA","BURL","VKTX","HEI","FLO","LU0310799852.SGD","BK4566","LU0211327993.USD","SG9999003800.SGD","CVI","APLS","SRPT","LU2237443978.SGD","UA","LU0175139822.USD","WMT","OLMA","BK4550","CPRT","BKKT","SG9999011175.SGD","LU0097036916.USD","WMS","LU2041044095.USD","LU2237443622.USD"],"gpt_icon":0},{"id":"2435702493","title":"Apellis Pharmaceuticals, Inc.2024财年第一财季实现净利润-66.42百万美元，同比增加62.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435702493","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435702493?lang=zh_cn&edition=full","pubTime":"2024-05-14 00:24","pubTimestamp":1715617442,"startTime":"0","endTime":"0","summary":"3月31日，Apellis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第一财季净利润为-66.42百万美元，同比增加62.69%；其中营业收入为1.72亿美元，同比增加283.50%，每股基本收益为-0.54美元。从资产负债表来看，Apellis Pharmaceuticals, Inc.总负债5.65亿美元，其中短期债务83.54百万美元，资产负债比为1.48，流动比率为3.78。机构评级：截至2024年3月31日，当前有17家机构对Apellis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为80.54美元，其中最低目标价为50.00美元，最高目标价为116.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405140024118b02725c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405140024118b02725c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"2434577065","title":"HC Wainwright & Co.：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价92.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434577065","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434577065?lang=zh_cn&edition=full","pubTime":"2024-05-09 03:15","pubTimestamp":1715195737,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价92.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050903154087e16a7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050903154087e16a7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"2433201957","title":"Apellis Pharmaceuticals, Inc.盘中异动 急速下跌5.01%报41.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433201957","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433201957?lang=zh_cn&edition=full","pubTime":"2024-05-08 22:57","pubTimestamp":1715180275,"startTime":"0","endTime":"0","summary":"北京时间2024年05月08日22时57分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.01%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082257567a58c5f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082257567a58c5f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","APLS","BK4139","BK4588","LU1093756168.USD","LU1093756325.SGD","BK4585"],"gpt_icon":0},{"id":"2433450788","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌7.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433450788","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433450788?lang=zh_cn&edition=full","pubTime":"2024-05-07 21:30","pubTimestamp":1715088623,"startTime":"0","endTime":"0","summary":"北京时间2024年05月07日21时30分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速下跌7.60%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240507213023861eb743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240507213023861eb743&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","LU1093756325.SGD","APLS","BK4585","LU1093756168.USD","BK4505"],"gpt_icon":0},{"id":"2432662901","title":"Apellis Pharmaceuticals Inc    预计每股亏损 52 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432662901","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432662901?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:55","pubTimestamp":1714748139,"startTime":"0","endTime":"0","summary":"   * Apellis Pharmaceuticals Inc    将于5月7日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* LSEG 分析师对 Apellis Pharmaceuticals Inc 的平均预期是每股亏损 52 美分。* 华尔街对 Apellis Pharmaceuticals Inc 的 12 个月目标价中位数为 84.00 美元，高于其上次收盘价 47.49 美元。5月3日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS"],"gpt_icon":0},{"id":"2431267943","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.14%报45.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431267943","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431267943?lang=zh_cn&edition=full","pubTime":"2024-04-30 21:45","pubTimestamp":1714484714,"startTime":"0","endTime":"0","summary":"北京时间2024年04月30日21时45分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.14%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021451579258605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021451579258605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1093756325.SGD","LU1093756168.USD","BK4585","APLS","BK4588","BK4505"],"gpt_icon":0},{"id":"2430072302","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.03%报50.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430072302","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430072302?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:54","pubTimestamp":1714146846,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日23时54分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426235406861e9966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426235406861e9966&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","APLS","LU1093756168.USD","BK4588","LU1093756325.SGD","BK4505"],"gpt_icon":0},{"id":"2430282069","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.05%报47.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430282069","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430282069?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:35","pubTimestamp":1714055747,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日22时35分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.05%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.84%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252235487a55b949&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252235487a55b949&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","BK4585","LU1093756168.USD","LU1093756325.SGD","APLS","BK4139"],"gpt_icon":0},{"id":"2428378134","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.00%报49.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428378134","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2428378134?lang=zh_cn&edition=full","pubTime":"2024-04-18 03:11","pubTimestamp":1713381116,"startTime":"0","endTime":"0","summary":"北京时间2024年04月18日03时11分，Apellis Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：Wedbush：维持Apellis Pharmaceuticals评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180311567a538294&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180311567a538294&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","APLS","BK4588","BK4585","LU1093756168.USD","BK4505","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.0738},{"period":"1month","weight":-0.0268},{"period":"3month","weight":-0.2395},{"period":"6month","weight":-0.443},{"period":"1year","weight":0.0773},{"period":"ytd","weight":-0.3811}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.1427},{"period":"1year","weight":0.2266},{"period":"ytd","weight":0.1669}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过在补体级联中的中心蛋白C3水平上抑制补体系统（作为免疫系统的一个组成部分）来治疗具有高度未满足需求的疾病。2023年2月，美国食品药品监督管理局（FDA）批准了SYFOVRE，这是首个获批治疗继发于年龄相关性黄斑变性（GA）的地理萎缩的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.018331},{"month":2,"riseRate":0.714286,"avgChangeRate":0.056236},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044074},{"month":4,"riseRate":0.714286,"avgChangeRate":0.062825},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.025158},{"month":6,"riseRate":0.714286,"avgChangeRate":0.080149},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.109018},{"month":8,"riseRate":1,"avgChangeRate":0.171387},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.124118},{"month":10,"riseRate":0.5,"avgChangeRate":0.026944},{"month":11,"riseRate":0.666667,"avgChangeRate":0.131706},{"month":12,"riseRate":0.857143,"avgChangeRate":0.150428}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}